Inactive Instrument

Highlights Fennec Pharmaceuticals Inc Other OTC

Equities

CA31447P1009

Real-time Estimate Cboe BZX Other stock markets 01:22:14 2024-04-29 pm EDT			5-day change	1st Jan Change
9.17 ^USD	+29.52%		+3.66%	+10.97%

Apr. 23	Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing	MT
Apr. 19	Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wedbush on Fennec's Q4	Mar. 21	MT
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share	Mar. 21	MT
Fennec Pharmaceuticals Brief: Cited Pro forma fourth quarter cash in excess of US$55 million	Mar. 21	MT
Fennec Pharmaceuticals Brief: Achieved PEDMARK Full-Year 2023 Net Product Sales of US$21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023	Mar. 21	MT
North American Morning Briefing : Investors -2-	Mar. 21	DJ
Fennec Pharmaceuticals Brief: Net losses for the fourth quarter and year ended December 31, 2023, of US$2.7 million ($0.10 per share) and $16.0 million ($0.60 per share), respectively	Mar. 21	MT
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21	CI
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21	CI
Fennec Pharmaceuticals, Norgine in Exclusive Licensing Agreement to Commercialize Pedmarqsi in Europe, Australia, and NZ	Mar. 18	MT
Fennec Pharmaceuticals Brief: Fennec Pharmaceuticals and Norgine Over the Weekend Entered into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand	Mar. 18	MT
Fennec Pharmaceuticals Inc. and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand	Mar. 17	CI
Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023	Feb. 29	CI
Fennec Pharmaceuticals Brief: Full-year 2023 net revenues are expected to be approximately US$20.7 to $21.2 million	Feb. 29	MT
Fennec Pharmaceuticals Brief: Q4 2023 net revenues are expected to be approximately US$9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023	Feb. 29	MT
Wedbush Maintains Outperform on Fennec Pharmaceuticals	Feb. 01	MT
FDA Issues Reminder of Non-Substitution of Fennec Pharmaceuticals' Pedmark For Pediatric Patients Receiving Cisplatin	Feb. 01	MT
Fennec Pharmaceuticals Brief: Says FDA Issues Reminder of Non-Substitution of PEDMARK (sodium thiosulfate injection) for Pediatric Patients Receiving Cisplatin	Feb. 01	MT
Fennec Pharmaceuticals Inc. Announces U.S. Food and Drug Administration Issues Reminder of Non-Substitution of PEDMARK®? (Sodium Thiosulfate Injection) for Pediatric Patients Receiving Cisplatin	Feb. 01	CI
Fennec Pharmaceuticals Reports Pedmark Net Product Revenue of US$6.5 Million In Q3 2023	Nov. 06	MT
Fennec Pharmaceuticals Brief: Anticipates that Cash, cash equivalents and investment securities as of September 30, 2023, when coupled with PEDMARK revenue assumptions will be sufficient to fund plans for at least the next 12 months	Nov. 06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fennec Pharmaceuticals Inc Other OTC

Equities

CA31447P1009

Highlights

Filters